All questions
Specific populations: Stelara (ustekinumab) in plaque psoriasis
2 questions · 2 sources
Specific populations questions that apply to every indication of Stelara are on Stelara (ustekinumab), all indications: Specific populations.
Pediatric use
What side effects did children have on Stelara for psoriasis?
Applies to Pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
“The safety of STELARA® was assessed in a study of 44 patients from 6 to 11 years of age (CADMUS Jr) and in a study of 110 patients from 12 to 17 years of age (CADMUS) with moderate to severe plaque psoriasis. The safety profile in these patients through Week 56 or Week 60, respectively, was similar to the safety profile from studies in adults with plaque psoriasis1,2
In CADMUS Jr (patients ages 6 to 11), through Week 56, 29 (65.9%) patients reported 1 or more AEs that were considered infections by the investigator. The most common AEs that were considered to be infections were nasopharyngitis (11 [25.0%] subjects), pharyngitis (6 [13.6%] subjects), and upper respiratory tract infection (6 [13.6%] subjects)1
In CADMUS (patients ages 12 to 17), through Week 12, the most common AEs were nasopharyngitis (STELARA®, 2.8% [1/36]; placebo, 27.0% [10/37]) and headache (STELARA®, 8.3% [3/36]; placebo, 5.4% [2/37]). Through Week 60, the most common AEs across all treatment arms were nasopharyngitis (34.5% [38/110]), upper respiratory tract infection (12.7% [14/110]), and pharyngitis (8.2% [9/110])2,3” (opens the source at this quote in a new tab)
How young can children start Stelara for plaque psoriasis?
Applies to Pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy